Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 on Long Term Immunogenicity. An Uncontrolled, Open-label Phase 3 Study.
Phase of Trial: Phase III
Latest Information Update: 09 May 2016
At a glance
- Drugs IC 51 (Primary)
- Indications Japanese encephalitis
- Focus Therapeutic Use
- Sponsors Intercell; Valneva
- 09 May 2016 New trial record
- 02 Apr 2008 Status changed from recruiting to active, not recruiting.